Cost-effectiveness of sorafenib for second-line treatment of advanced renal ... - UroToday PDF Print
UroToday... versus best supportive care (BSC) for second-line treatment of advanced renal cell carcinoma from the perspective of the UK National Health Service.

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.